Anika Therapeutics ANIK Balance Sheet Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| $38.41M-27.8% | $41.02M-23.1% | $57.48M+3.3% | $57.99M-7.0% | $53.17M-15.4% | ||
| —— | $25.77M+17.2% | $23.69M+0.4% | $22.19M-21.8% | $23.96M-29.1% | ||
| $3.23M— | $2.18M+172% | —— | -$1.29M+72.9% | —— | ||
| -$16.83M-199% | $22.84M+7.0% | $18.79M-21.1% | $16.28M-58.9% | $16.92M-67.1% | ||
| $99.19M-0.1% | $93.56M-8.7% | $103.36M-9.1% | $101.59M-25.4% | $99.32M-35.9% | ||
| $40.1M-1.4% | $39.72M-1.8% | $40.32M+3.4% | $40.68M-8.7% | $40.68M-14.7% | ||
| $7.83M-2.9% | $7.89M+6.3% | $8.05M+13.0% | $8.05M+5.2% | $8.06M+9.6% | ||
| $1.65M-0.7% | $1.65M-27.7% | $1.65M-33.7% | $1.65M-46.4% | $1.66M-58.2% | ||
| $183.47M-2.2% | $179.39M-5.9% | $190.27M-6.2% | $189.44M-18.1% | $187.68M-28.5% | ||
| $6.24M+30.7% | $6.34M+20.1% | $6.04M+7.5% | $4.73M-30.5% | $4.77M-52.3% | ||
| $22.15M+37.7% | $20.97M+17.1% | $21.91M-6.0% | $19.09M-25.1% | $16.08M-38.4% | ||
| $134K-6.9% | $133K-7.0% | $139K-3.5% | $144K-2.0% | $144K-2.7% | ||
| $59.04M-6.0% | $55.73M-16.6% | $60.79M-15.2% | $60.5M-35.3% | $62.82M-49.1% | ||
| $137.28M-7.0% | $133.9M-9.8% | $143.47M-6.8% | $146.81M-18.4% | $147.67M-29.8% | ||
| $183.47M-2.2% | $179.39M-5.9% | $190.27M-6.2% | $189.44M-18.1% | $187.68M-28.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Anika Therapeutics's total assets?
- Anika Therapeutics (ANIK) holds $183.5M in total assets, down 2.2% year over year.
- How much cash does Anika Therapeutics have?
- Anika Therapeutics holds $38.4M in cash and equivalents.
- Can Anika Therapeutics cover its short-term obligations?
- Its current ratio is 4.48 — current assets exceed current liabilities.
- Where does Anika Therapeutics's balance sheet data come from?
- Every line is extracted from Anika Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
